About

About Brainomix Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in lung fibrosis and stroke. With origins as a spin-out from the University of Oxford, Brainomix has innovated award-winning imaging biomarkers and software solutions that have been clinically adopted in hundreds of hospitals worldwide. Brainomix e-Lung is an FDA-cleared, AI-powered imaging software platform that automatically identifies and quantifies features on CT lung scans associated with Interstitial Lung Disease (ILD). Results from REVISE PPF, a multicenter study presented at CHEST and ERS, showed e-Lung could have supported an earlier diagnosis of PPF in 71% of patients and up to 28 months earlier. Brainomix is an Oxford-based company specializing in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions in stroke, lung fibrosis and cancer.